Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate for Fatigue in Cancer Patients
NCT00516269Phase 3Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2004
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet in fatigue (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Mean Difference Between Post-Methylphenidate and Post-Placebo Measurement at 4 weeks. Started Aug 2004; status: terminated.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
fatigue
Beyond the preview
Go deeper on NCT00516269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00516269.